Some marijuana products were placed in Schedule III in April 2026, but that did not complete the broader federal proposal to move marijuana out of Schedule I. The Department of Justice said its April action covered FDA-approved marijuana products and products regulated under qualifying state-issued medical marijuana licenses. A separate DEA rulemaking would cover the broader proposal; the official materials available for this article do not confirm whether a final decision followed its July 2026 hearing.
Has marijuana been rescheduled to Schedule III?
Not across the board, based on the official status available here. In April 2026, the Department of Justice announced an immediate Schedule III action for two defined categories: FDA-approved marijuana products and marijuana products regulated under qualifying state-issued medical marijuana licenses. DOJ separately described a hearing process for the broader proposal to transfer marijuana from Schedule I to Schedule III. DOJ’s announcement makes clear that the limited action and broader proposal are distinct.
The distinction matters: an agency announcement covering certain products is not a final decision on every form of marijuana. The DEA rescheduling page describes the broader matter as a proposed rulemaking and documents the hearing schedule, but the official sources reviewed do not establish a post-hearing final order or effective date. Check for a newer DEA order or Federal Register notice before treating that broader transfer as complete.
What did Trump’s executive order do?
On December 18, 2025, President Donald Trump signed Executive Order 14370, Increasing Medical Marijuana and Cannabidiol Research. It directed the Attorney General to take the necessary steps to complete the broader Schedule III rulemaking as expeditiously as federal law allows. It did not itself complete that rulemaking or put all marijuana in Schedule III. The order said the 2024 proposal had received nearly 43,000 public comments and was awaiting an administrative law hearing at that time; that is a White House figure from 2025, not a current comment count.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minute#1 Best Overall
How the limited action differs from the broader proposal
| Issue | April 2026 action | Broader Schedule I-to-III proposal |
|---|---|---|
| Scope | FDA-approved marijuana products and products regulated under qualifying state-issued medical marijuana licenses, as described by DOJ. | The broader proposal to transfer marijuana from Schedule I to Schedule III; the final scope and outcome are not established by the sources reviewed. |
| Status | DOJ announced the action as immediate in April 2026. | DEA described it as a proposed rulemaking; the reviewed official materials do not confirm a final post-hearing decision. |
| Key official record | DOJ’s April 2026 announcement. | DEA’s rescheduling page and the rulemaking record. |
| Hearing or effective-date information | DOJ described this as a separate action; a broader-rule hearing date does not define the limited action’s status. | DEA scheduled a hearing beginning June 29, 2026, to conclude no later than July 15, subject to continuation or recess by the administrative law judge. That schedule is not itself a final order or effective date. |
What was the hearing—and did it settle the question?
The broader proposal originated in a May 21, 2024 DOJ notice seeking to transfer marijuana from Schedule I to Schedule III. DEA says the proposal reflected the Department of Health and Human Services’ view that marijuana has a currently accepted medical use and its assessment of abuse and dependence potential. A formal hearing is part of the rulemaking process for considering the proposal and building its record; its scheduled end does not mean the proposal automatically takes effect.
DEA’s published schedule set the hearing for June 29 through no later than July 15, 2026, while allowing the presiding administrative law judge to continue or recess it. The sources available for this article do not show what happened after that schedule or whether DEA or DOJ later issued a final decision. The broader status therefore remains unconfirmed here; rely on a current final DEA order or Federal Register notice for an outcome or effective date.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Does this mean recreational marijuana is federally legal?
No such conclusion follows from the actions described above. DOJ said strict federal controls remain, and the April 2026 announcement was limited to the specified FDA-approved and qualifying state-licensed medical products. Neither that announcement nor Trump’s direction to complete a rulemaking is evidence that recreational marijuana is federally legalized, that all federal controls have disappeared, or that state marijuana laws have changed. Those questions require separate, current legal authority.
Quick Recap
What to check for the latest status
- Look for a final DEA order or a Federal Register notice addressing the broader Schedule I-to-III proposal.
- Confirm the document’s scope, publication date, and effective date; do not infer them from a hearing deadline or the 2025 executive order.
- For the April action, use DOJ’s stated categories rather than assuming it applies to every marijuana product.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
